Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Apple Tree Partners
AddedFeb 15, 2024
UpdatedJun 28, 2026
Apple Tree Partners

Apple Tree Partners

Operating

Apple Tree Partners: Investing in healthcare and manufacturing traffic management systems.

Location
New York City, NY, US
Founded
1999
Firm
Compare
Portfolio
Fundraising
Employees
Website

Investments

Deep Apple Therapeutics
Deep Apple Therapeutics

Total Raised

$52M

Rounds

1

Series A$52MDecember 2023
Ascidian Therapeutics
Ascidian Therapeutics

Total Raised

$90M

Rounds

3

Series A$40MNovember 2023
Series A$50MOctober 2022
SeedJanuary 2021
Aulos Bioscience
Aulos Bioscience

Total Raised

$60M

Rounds

2

Series A$20MAugust 2023
Series A$40MJanuary 2021
Initial Therapeutics
Initial Therapeutics

Total Raised

$78.8M

Rounds

2

Series A$75MMay 2023
Seed$3.8MJuly 2020
Aethon Therapeutics
Aethon Therapeutics

Total Raised

$30M

Rounds

1

Series A$30MJanuary 2023
Galvanize Therapeutics
Galvanize Therapeutics

Total Raised

$148.5M

Rounds

4

Series B$100MSeptember 2022
Marengo Therapeutics
Marengo Therapeutics

Total Raised

$80M

Rounds

2

Series B$80MNovember 2021
SeedJanuary 2021
Intergalactic Therapeutics
Intergalactic Therapeutics

Total Raised

$75M

Rounds

2

Series A$75MOctober 2021
SeedJanuary 2021
Replicate Bioscience
Replicate Bioscience

Total Raised

$46M

Rounds

2

Series A$40MSeptember 2021
Seed$6MFebruary 2021
Nereid Therapeutics
Nereid Therapeutics

Total Raised

$50M

Rounds

1

Series A$50MNovember 2020
Nine Square Therapeutics
Nine Square Therapeutics

Total Raised

$54.5M

Rounds

2

Series A$50MJuly 2020
Limelight Bio
Limelight Bio

Total Raised

$89M

Rounds

2

Series Unknown$75MDecember 2019
Stoke Therapeutics
Stoke Therapeutics
Public

Total Raised

$235.1M

Rounds

4

Series B$90MOctober 2018
Series A$40MJanuary 2018
Braeburn
Braeburn

Total Raised

$133M

Rounds

2

Debt Financing$110MJanuary 2018
Elstar Therapeutics
Elstar Therapeutics

Total Raised

$39M

Rounds

1

Series A$39MJanuary 2018
Rox Medical
Rox Medical

Total Raised

$96.7M

Rounds

6

Series E$40MSeptember 2016
VytronUS
VytronUS

Total Raised

$115.4M

Rounds

7

Series C$49MJuly 2016